Zelnick Kaufman Beth 4

What Happened
Beth Zelnick Kaufman, Chief Legal Officer of CorMedix, received an award of 36,006 shares (recorded as performance stock units) on February 4, 2026. The reported acquisition price is $0.00 (i.e., an awarded grant rather than a purchase), so the immediate cash value reported is $0. This is an equity compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (Accession 0001213900-26-013408).
• Shares/units awarded: 36,006; reported acquisition price: $0.00.
• Shares owned after transaction: Not reported in the information provided.
• Footnote: The award reflects achievement of PSUs for the first of three performance periods for PSUs granted 01/02/2025; these PSUs remain subject to vesting based on time-based conditions.
• Filing timeliness: Filed two days after the transaction date, which appears timely for a Form 4.

Context
Performance stock units (PSUs) are compensation tied to company performance and typically only convert into actual shares if performance and vesting conditions are met; they are not the same as an immediate market purchase. Awards like this are common as part of executive compensation and should be viewed as compensation-related grants rather than a direct personal cash investment or sale.